Literature DB >> 22020992

The acute effects of 3,4-methylenedioxymethamphetamine and d-methamphetamine on human cognitive functioning.

Con Stough1, Rebecca King, Katherine Papafotiou, Phillip Swann, Edward Ogden, Keith Wesnes, Luke A Downey.   

Abstract

RATIONALE: This study investigated the acute (3-h) and 24-h post-dose cognitive effects of oral 3,4-methylenedioxymethamphetamine (MDMA), d-methamphetamine, and placebo in a within-subject double-blind laboratory-based study in order to compare the effect of these two commonly used illicit drugs on a large number of recreational drug users.
METHODS: Sixty-one abstinent recreational users of illicit drugs comprised the participant sample, with 33 females and 28 males, mean age 25.45 years. The three testing sessions involved oral consumption of 100 mg MDMA, 0.42 mg/kg d-methamphetamine, or a matching placebo. The drug administration was counter-balanced, double-blind, and medically supervised. Cognitive performance was assessed during drug peak (3 h) and at 24 h post-dosing time-points. Blood samples were also taken to quantify the levels of drug present at the cognitive testing time-points.
RESULTS: Blood concentrations of both methamphetamine and MDMA at drug peak samples were consistent with levels observed in previous studies. The major findings concern poorer performance in the MDMA condition at peak concentration for the trail-making measures and an index of working memory (trend level), and more accurate performance on a choice reaction task within the methamphetamine condition. Most of the differences in performance between the MDMA, methamphetamine, and placebo treatments diminished by the 24-h testing time-point, although some performance improvements subsisted for choice reaction time for the methamphetamine condition.
CONCLUSIONS: Further research into the acute effects of amphetamine preparations is necessary to further quantify the acute disruption of aspects of human functioning crucial to complex activities such as attention, selective memory, and psychomotor performance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020992     DOI: 10.1007/s00213-011-2532-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  41 in total

1.  Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK.

Authors:  A R Winstock; P Griffiths; D Stewart
Journal:  Drug Alcohol Depend       Date:  2001-09-01       Impact factor: 4.492

Review 2.  MDMA use and neurocognition: a meta-analytic review.

Authors:  Ari D Kalechstein; Richard De La Garza; James J Mahoney; William E Fantegrossi; Thomas F Newton
Journal:  Psychopharmacology (Berl)       Date:  2006-11-03       Impact factor: 4.530

Review 3.  A review of the clinical pharmacology of methamphetamine.

Authors:  Christopher C Cruickshank; Kyle R Dyer
Journal:  Addiction       Date:  2009-04-29       Impact factor: 6.526

4.  The acute effects of 3,4-methylenedioxymethamphetamine and methamphetamine on driving: a simulator study.

Authors:  Con Stough; Luke A Downey; Rebecca King; Katherine Papafotiou; Phillip Swann; Edward Ogden
Journal:  Accid Anal Prev       Date:  2011-09-19

5.  Amphetamine toxicity.

Authors:  Suzanne R White
Journal:  Semin Respir Crit Care Med       Date:  2002-02       Impact factor: 3.119

6.  MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study.

Authors:  Andrew C Parrott; Amy Gibbs; Andrew B Scholey; Rebecca King; Katherine Owens; Phil Swann; Ed Ogden; Con Stough
Journal:  Psychopharmacology (Berl)       Date:  2011-02-12       Impact factor: 4.530

7.  The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers.

Authors:  K A Wesnes; T Ward; A McGinty; O Petrini
Journal:  Psychopharmacology (Berl)       Date:  2000-11       Impact factor: 4.530

Review 8.  Human research on MDMA (3,4-methylene- dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change.

Authors:  A C Parrott
Journal:  Neuropsychobiology       Date:  2000       Impact factor: 2.328

9.  Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial.

Authors:  Con Stough; Luke A Downey; Jenny Lloyd; Beata Silber; Stephanie Redman; Chris Hutchison; Keith Wesnes; Pradeep J Nathan
Journal:  Phytother Res       Date:  2008-12       Impact factor: 5.878

10.  Patterns of ecstasy use in Australia: findings from a national household survey.

Authors:  Louisa Degenhardt; Bridget Barker; Libby Topp
Journal:  Addiction       Date:  2004-02       Impact factor: 6.526

View more
  4 in total

1.  The acute effects of MDMA and ethanol administration on electrophysiological correlates of performance monitoring in healthy volunteers.

Authors:  D B Spronk; G J H Dumont; R J Verkes; E R A De Bruijn
Journal:  Psychopharmacology (Berl)       Date:  2014-04-26       Impact factor: 4.530

2.  Endogenous serotonin facilitates hippocampal long-term potentiation at CA3/CA1 synapses.

Authors:  Boris Mlinar; Gabriella Stocca; Renato Corradetti
Journal:  J Neural Transm (Vienna)       Date:  2014-05-29       Impact factor: 3.575

3.  Repeated Acquisition in the Morris Swim Task: Effects of MDMA, Methamphetamine and Methylphenidate.

Authors:  Mark Galizio; Bridget D Byrd; Andrea M Robinson; Andrew Hawkey; Rebecca Rayburn-Reeves; L Brooke April
Journal:  Psychol Rec       Date:  2014-06-01

4.  The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study.

Authors:  Aurora J A E van de Loo; Adriana C Bervoets; Loes Mooren; Noor H Bouwmeester; Johan Garssen; Rob Zuiker; Guido van Amerongen; Joop van Gerven; Jaskaran Singh; Peter Van der Ark; Maggie Fedgchin; Randall Morrison; Ewa Wajs; Joris C Verster
Journal:  Psychopharmacology (Berl)       Date:  2017-07-28       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.